Fowler Daptomycin
2006
Daptomycin versus Standard Therapy for Bacteraemia and Endocarditis Caused by Staphylococcus aureus
In 246 patients with Staphylococcus aureus bacteraemia with or without endocarditis, daptomycin was non-inferior to an antistaphylococcal penicillin or vancomycin plus initial low-dose gentamicin for treatment success 42 days after the end of therapy, with less renal toxicity.
Result
- Absolute difference
- 2.5 points
absolute difference2.495% CI -10.2 to 15.1
The absolute difference is derived from the event rates.
Also reported: Non-inferiority met. Clinically significant renal dysfunction 11.0 % vs 26.3 % (p=0.004).
- Subtopic
- Antibiotic therapy
- Design
- Open-label non-inferiority RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2023 Endocarditis
- Source
- Fowler VG Jr, Boucher HW, Corey GR, et al. N Engl J Med. 2006;355(7):653-665.doi 10.1056/NEJMoa053783
Discussion & critique
Open-label and underpowered for the endocarditis subgroup, most of which was right-sided, so left-sided and prosthetic-valve disease remain untested. The nephrotoxicity of its gentamicin-containing control arm is a principal reason routine aminoglycoside combination therapy was abandoned in native-valve staphylococcal endocarditis.